natgillin/translations-raw huggingface dataset:
An anthranilamide compound represented by the formula (Ia) or its salt: wherein R1 is halogen or alkyl; each of R2 and R3 is halogen or CF3; A is alkyl substituted by Y; Y is cyclopropyl which may be substituted by halogen or alkyl; m is 1 or 2; n is 0 or 1, provided that when R1 is a fluorine atom, a chlorine atom, a bromine atom or methyl substituted at the 2-position of the benzene ring and another R1 is halogen substituted at the 4-position of the benzene ring, the halogen at the 4-position is a fluorine or a chlorine atom. 
Antranilamidni spoj, naznačen time, da je predstavljen formulom (Ia) ili sol istog: [image] pri čemu R1 je halogen ili alkil; svaki od R2 i R3 je halogen ili CF3; A je alkil supstituiran s Y; Y je ciklopropil koji može biti supstituiran s halogenom ili alkilom; m je 1 ili 2; n je 0 ili 1, pod uvjetom da kada je R1 atom fluora, atom klora, atom broma ili metil supstituiran na 2-om položaju benzenskog prstena i drugi R1 je halogen supstituiran na 4-om položaju benzenskog prstena, halogen na 4-om položaju je atom fluora ili atom klora.
A compound having a structure represented by a formula: wherein Ar1 is selected from 3-pyridinyl, 4-isoxazolyl, N-methyl-4-pyrazolyl, 4-pyrazolyl, 4-isothiazolyl, 5-thiazolyl, 5-pyrimidinyl, and 4-pyridazinyl; R1 is selected from CF3 and (CH3)2CH; R2 and R3 are independently selected from H, OCH3 and F; Ar2 has a structure represented by a formula: wherein R4a, R4b and R5 are independently selected from H, CN, F, Cl and OCF3, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, as well as tautomers, geometrical isomers, optically active forms thereof, as well as tautomers, geometrical isomers, optically active forms thereof. 
i N-(3-cijano-4-fluorofenil)-1-okso-3-(1H-pirazol-4-il-6,7-difluoro-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid Spoj koji ima strukturu predstavljenu formulom: [image] naznačen time da je Ar1 izabran od 3-piridinila, 4-izoksazolila, N-metil-4-pirazolila, 4-pirazolila, 4-izotiazolila, 5-tiazolila, 5-pirimidinila, i 4-piridazinila; R1 je izabran od CF3 i (CH3)2CH; R2 i R3 su nezavisno izabrani od H, OCH3 i F; Ar2 ima strukturu predstavljenu formulom:
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added prior to, during or after, and preferably after, a step of grinding said calcium carbonate-comprising material in said suspension. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni 2-((1- metilpropil)amino)etanol dodan prije, za vrijeme ili nakon, poželjno nakon koraka mrvljenja navedenog materijala koji sadrži kalcijev karbonat u navedenu otopinu.
A liquefied gas treatment system for a vessel, which includes a cargo tank storing liquefied natural gas, and an engine using the liquefied natural gas stored in the cargo tank as fuel, the liquefied gas treatment system comprising: 
Sustav za obradu ukapljenog plina za plovilo, koji sadrži spremnik za teret (1;11), u kojem je spremljen ukapljeni zemni plin (LNG), te glavni motor (3) i pomoćni motor (200) koji koristi LNG spremljen u spremniku za teret kao gorivo, gdje sustav za obradu ukapljenog plina sadrži:
A solid cosmetic composition according to any one of claims 1 to 7 wherein the outer layer comprises colouring in an amount of from 0.001 to 5 wt.% based on the outer layer; and/or wherein the colouring in the outer layer is an oil soluble colouring. 
Čvrsti kozmetički pripravak prema bilo kojem od zahtjeva 1 do 7 naznačen time što vanjski sloj sadrži bojilo u količini od 0.001 do 5 mas.% u odnosu na vanjski sloj; i/ili pri čemu je bojilo u vanjskom sloju bojilo koje je topivo u ulju.
The high-modulus glass fiber composition of claim 1, wherein, comprising the following components expressed as weight percentage: SiO2 
Pripravak od fiberglasa visokih svojstava sukladno zahtjevu 1, pri čemu, obuhvaća sljedeće komponente izražene kroz težinske postotke:
The solid oral extended release pharmaceutical dosage form of anyone of claims 1 to 16, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25°C i 60 % relativne vlažnosti (RH) lijekom najmanje 1 mjeseca sadrži količinu od najmanje jednog aktivnog sredstva u % (težinski) u odnosu na deklaracijski zahtjev aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije veće od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog sredstva u % (težinski) relativno prema deklaracijskom zahtjevu aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije pohranjivanja.
of a nucleic acid which codes for the tumor-associated antigen or of a part thereof, and/or of the tumor-associated antigen or of a part thereof, and/or 
In vitro postupak za dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom, pri čemu taj postupak sadrži detekciju ili određivanje količine nukleinske kiseline koja kodira antigen povezan sa tumorom, i/ili
Because the anti-diabetic efficacy of PPARY full agonists are known to be accompanied by significant weight gain and plasma volume expansion, the data herein indicates that compound of formula V could provide an improved therapy for the treatment of type 2 diabetes compared to the currently marketed or available PPARY agonists. 
Kako se zna da je antidijabetično djelovanje punih agonista PPARy popraćeno značajnim porastom tjelesne težine i povećanjem volumena plazme, dobiveni podaci ukazuju da bi spoj formule V mogao osigurati poboljšanu terapiju u liječenju dijabetesa tipa 2 u usporedbi s agonistima PPARYy koji su trenutno dostupni ili prisutni na tržištu.
For the orthogonal arrangement structure which is illustrated in Figure 2c, nothing is changed in the production process according to the invention, and these considerations can be applied correspondingly. 
Za okomitu strukturu naprave, koja je prikazana na slici 2c, ništa se ne mijenja u proizvodnom postupku prema izumu, i ta se razmatranja mogu odgovarajuće primijeniti.
instructions for using the pharmaceutical composition of (a) for the treatment of a condition selected from the group consisting of: ischemic heart conditions; 
(b) instrukcija za uporabu farmaceutskog pripravka iz (a) za liječenje stanja koje je odabrano iz skupine koju čine:
Use according to claim 3, in which the composition is for oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, transcutaneous, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration. 
Upotreba u skladu s patentnim zahtjevom 3, naznačena time što je pripravak namijenjen za oralnu, intravensku, intramuskularnu, intraarterijsku, intramedularnu, intratekalnu, intraventrikulsku, transdermalnu, transkutanu, supkutanu, intraperitonealnu, intranazalnu, enteralnu, topikalnu, sublingvalnu ili rektalnu primjena.
Use of aminopyridine in the manufacture of a sustained release composition for treating multiple sclerosis, wherein said composition is administered twice daily in a dose of 10 milligrams or less of aminopyridine. 
Upotreba aminopridina u proizvodnji sastava s odgođenim oslobađanjem za tretiranje multiple skleroze, naznačena time da je sastav primijenjen dvaput dnevno u dozi od 10 miligrama ili manjoj, aminopiridina.
Preparation of the precipitation buffer solution: 
Datum objave europskog patenta:
The compound or salt of claim 48 wherein said disease is a myeloproliferative disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu je bolest mijeloproliferativni poremećaj.
The process as claimed in claim 4, wherein said base is selected from potassium carbonate, sodium bicarbonate and sodium hydride, or wherein said inert solvent is selected from tetrahydrofuran, toluene, ethyl acetate, water, dimethylformamide, dimethyl sulfoxide and dimethyl ether. 
Postupak u skladu sa patentnim zahtjevom 4, naznačen time, što je navedena baza izabrana iz kalijevog karbonata, natrijevog bikarbonata i natrijevog hidrida. ili pri čemu je navedeno inertno otapalo izabrano iz tetrahidrofurana, toluena. etil acetata. vode, dimetilformamida, dimetil sulfoksida i dimetil etera.
All procedures were performed on mice of at least 8 weeks of age. 
Svi postupci provođeni su na miševima starim najmanje osam tjedana.
The optical element (OP) according to any of the preceding claims, wherein the reflector is provided to a lower portion of the optical element. 
Informacijski sustav u skladu sa bilo kojim od patentnih zahtjeva 1 do 8, gdje je reflektor osiguran na nižem dijelu optičkog elementa.
The topical gel composition of claim 6, wherein the total polyol comprises about 4.5% to 6.5% (w/w) a first polyol. 
Kompozicija topičkog gela prema zahtjevu 5, pri čemu kompozicija sadrži: od 0,05 do 5% (w/w) brimonidina ili brimonidin tartrata.
Furthermore, the compound may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable, e.g. in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. 
Nadalje, spoj može biti rabljen u tretmanu drugih crijevno-želučanih poremećaja gdje je poželjan protusekretorni želučani učinak, u pacijenata s gastrinomom i u pacijenata s akutnim crijevno-želučanim krvarenjem gornjih putova.
In some embodiments, the cancer is not a solid tumor (i.e., other than a solid tumor). In some embodiments, the cancer is a plasmacytoma. In some embodiments, the cancer is multiple myeloma, renal cell carcinoma, prostate cancer, lung cancer, melanoma, brain cancer (e.g., glioblastoma), ovarian cancer, or breast cancer. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je rak odabran iz skupine koju čine multipli mijelom, rak gušterače, karcinom bubrežnih stanica, rak prostate, rak pluća, melanom, rak mozga, rak jajnika, limfom, limfoidna neoplazma, mijelom, leukemija, neuroendokrini rak, raka štitnjače, mezoteliom, plazmocitom i sarkom.
The method according to one or more of claims 3-13, wherein the fabric, as well as the nonwoven fabric, which is used to provide said single element (18) or said localized elements (130a, 130b, 130c, 130d) is of any type depending on requirements and needs. 
Postupak prema jednom ili više od zahtjeva 3 do 13, naznačen time, da je tkanina, kao 1 netkani materijal, koji se koristi za dobivanje spomenutog izdvojenog elementa (18) ili spomenutih lokaliziranih elemenata (1304, 130b, 130c, 130d), bilo kojeg tipa ovisno o uvjetima i potrebama.
Process for the preparation of surface-treated calcium carbonate material comprising the following steps: providing at least one calcium carbonate-containing material; providing at least one salt of a C5 - C28 fatty acid selected from the group comprising mono-alcohol primary alkanolamine salts, polyethyleneimine salts, and mixtures thereof; 
Postupak za pripremanje materijala od površinski obrađenog kalcijevog karbonata naznačen time da se sastoji od slijedećih koraka: a) osiguravanja barem jednog materijala koji sadrži kalcijev karbonat; b) osiguravanja barem jedne soli Cs - C>g masne kiseline koja je odabrana iz skupine koja sadrži soli primarnog mono-alkohol alkanolamina, soli polietilenimina, te njihove smjese;
A compound represented by the following Formula (I): 
Sastav predstavljen slijedećom Formulom (1): pri čemu:
The pharmaceutical composition for use of claim 28, wherein the pulmonary disease or disorder is selected from at least one of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary vasoconstriction, pulmonary inflammation associated with cystic fibrosis, and pulmonary obstruction associated with cystic fibrosis. 
Ko-suspenzija za uporabu prema patentnom zahtjevu 30, naznačena time što se bolest ili stanje bira od astme, KOPB, pogoršanja hiper reaktivnosti dišnih putova kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, sindroma respiratornog distresa, plućne hipertenzije, i upale pluća i opstrukcije povezane s cističnom fibrozom.
A process for the preparation of crystalline Form I of a compound of formula I which comprises: addition of methyl-tert-butyl ether to a solution of the compound of formula I in ethyl acetate, cooling the reaction mixture obtained, filtering and drying the crystallized product. 
Proces dobijanja kristalne Forme I, prema zahtjevima 1-4, naznačen time što obuhvaća: dodavanje metil-terc-butil etera otopini spoja formule I u etil acetatu, hlađenje dobijene reakcijske smjese, filtriranje i sušenje kristaliziranog proizvoda.
The resultant oil was dissolved twice in 300 mL of toluene and reconcentrated to yield a thick oil (300g, 95% HPLC purity) that was used without further purification of the resulting impure diastereomeric mixture. 
Dobijeno ulje je otopljno dva puta u 300 ml toluena i rekoncentrirano da bi se dobilo gusto ulje (300g, 95% HPLC čistoća) koje je korišteno bez dodatnog prečišćavanja dobijene nečiste diastereomerne smjese.
contacting a GPR119 agonist in vitro with a vertebrate enteroendocrine cell or a cell capable of secreting GIP; and 
(a) stavljanje u doticaj agonista GPR119 in vitro sa enteroendokrinom stanicom kralježnjaka ili stanice sposobne za GIP sekreciju; i
determining whether the dependent slice segment is includable in the picture based on first information that is obtained from a picture parameter set of the bitstream; 
dobivanje, iz toka bitova, druge informacije koja ukazuje je li trenutna LCU posljednja LCU u prvom odsječku segmenta trenutne slike;
A nasal drug delivery device or a dose cartridge for use in a nasal drug delivery device comprising a composition as defined in any one of claims 1 to 18. 
. Uređaj za nazalno davanje lijeka ili dozni kartridž za upotrebu u uređaju za nazalno davanje lijeka koji se sastoji od kompozicije u bilo kojem od zahtjeva 1 do 18. tr>
Some reactions may be carried out in the presence of a base. 
Neke reakcije može se provesti u prisutnosti baze.
The method of claim 1, wherein the inflammatory bowel disease is Crohn's disease. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest Crohnova bolest.
a fibre-reinforced material comprising a resin matrix and fibres substantially uniformly directed, a fraction in a range of at least 40% and at most 80% by volume of a total content of said dental post comprising said fibres and at least a fraction of said fibres being configured to conduct light within said dental post; and 
Zubni potporanj u skladu s najmanje jednim od patentnih zahtjeva 1 do 13, naznačen time što navedeni potporanj se dodatno sastoji od matrice od kompozitne smole (9), gdje udio od najmanje 40%, a najviše 80% u volumenu po težini od ukupnog sadržaja čine navedena vlakna (8), uklopljena u navedenu matricu (9).
providing a granulation zone comprising particles, the particles being kept in motion; 
osiguravanje granulacijske zone (4) koja sadrži čestice, pri čemu su čestice u pokretu;
A method in accordance with claim 1, wherein the GPR119 agonist and the DPP-IV inhibitor are administered in amounts sufficient to lower a blood glucose level in the subject. 
Pripravak u skladu sa zahtjevom 32, naznačen time, da GPR119 agonist i DPP-IV inhibitor su u količinama dovoljnim da snize nivo glukoze u krvi kod subjekta.
The polypeptide according to claim 1 consisting of the amino acid sequence in SEQ ID NO: 11. 
Ne-humana transgena životinja prema zahtjevu18, naznačena time da navedeni APP je mutirani ljudski APP, poželjno pri čemu je navedeni APP protein iz SEQ ID NO: 11.
The placental stem cells for use according to any one of claims 1 to 4, wherein said method further comprises administering a second therapeutic agent. 
Matične stanice posteljice za uporabu u skladu s patentnim zahtjevom 2, naznačenu time što se navedena metoda nadalje sastoji od primjene drugog terapijskog agensa.
In Porath's work, IMAC consists of derivatizing a resin with iminodiacetic acid (IDA) and chelating metal ions to the IDA-derivatized resin. 
U njegovom radu, IMAC se sastoji od derivatizirajućeg nosača s iminodiacetnom kiselinom (IDA) te helatnim metalnim ionima koji se nalaze na IDA-derivatizirajućeg nosača.
Multiparticulates according to claim 12, wherein the percentage amounts of the ingredients (a) to (e) are as given in the following table, based on the total weight of the five ingredients: 
Muitičestice prema zahtjevu 11, gdje su količine sastojaka od (a) do (e) dane u postotcima u sljedećoj tablici, na temelju ukupne težine pet sastojaka:
A process according to claim 5, wherein the process comprises the step of automatically adjusting the dosage of the nutrient solution added to the H2S contaminated energy production gas stream in relation to the H2S content in the H2S contaminated energy production gas stream at an inlet of the biofilter system (10). 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da obuhvaća korak automatskog podešavanja doze otopine hranjivih tvari dodanih u struju plina za proizvodnju energije koja je onečišćena s H,S u odnosu na sadržaj H2S u struji plina za proizvodnju energije koja je onečišćena s H2S na ulazu biofiltra.
In this respect, openings may be closed again by closing or replacing a wall element and new openings may be created after completion of the building. 
U skladu s time, otvori se mogu ponovno zatvoriti zatvaranjem ili zamjenom zidnog elementa, a novi otvori mogu se izraditi nakon dovršenja gradnje.
some of the fibres which the high piles comprise are lighter in weight than the smallest fibres which the low piles comprise, characterized in that 
- < neka od vlakana u visokom floru imaju manju težinu od najmanjih vlakana u niskom floru, naznačen time, da
mapping the bit-interleaved L1 signaling data to constellation values corresponding to L1 signaling data; time interleaving the mapped constellation values corresponding to L1 signaling data by serially writing the constellation values corresponding to L1 signaling data into a memory in a diagonal direction and serially reading the written constellation values corresponding to L1 signaling data from the memo in a row direction according to Layer 1 Time Interleaving mode information, referred to as L1 TI mode information, that indicates a time interleaving depth, wherein a number of rows of the memory is equal to the time interleaving depth, wherein a number of columns of the memory is equal to a quotient resulting from dividing a number of constellation values corresponding to the L1 signaling data by the time interleaving depth, and wherein the time interleaving depth is equal or larger than a minimum number of OFDM symbols required for carrying a Layer 1 block including the L1 signaling data; 
FEC kodiranje signalnih podataka razine 1; navedenih kao LI signalni podaci; umetanje bitova u FEC-kodirane LI signalne podatke; mapiranje LI signalnih podataka s umetnutim bitovima u konstelacijske vrijednosti koje odgovaraju signalnim podacima L1; umetanje vremena u mapirane konstelacijske vrijednosti koje odgovaraju LI! signalnim podacima serijskim pisanjem konstelacijskih vrijednosti koje odgovaraju L1 signalnim podacima u memoriju u dijagonalnom smjeru i serijskim čitanjem zapisanih konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1l iz memorije u smjeru retka prema informaciji o vrsti umetanja vremena razine 1, navedene kao informacija vrste LI TI, koja ukazuje dubinu umetanja vremena, pri čemu je broj redaka memorije jednak dubini umetanja vremena, pri čemu je broj stupaca memorije jednak kvocijentu koji je rezultat dijeljenja broja konstelacijskih vrijednosti koje odgovaraju
A solution of 5-biphenyl-4-yl-3-oxo-pentanoic acid tert-butyl ester (13.7 g, 42.4 mmol) in dimethylformamide (10 mL) was added dropwise over 20 min to a stirred suspension of sodium hydride (60% mineral oil suspension; 1.78 g, 44.4 mmol) in dimethylformamide (10 mL) at 0° C. under nitrogen. 
Otopinu tert-butilnog estera 5-bifenil-4-il-3-oksopentanske kiseline (13,7 g, 42,4 mmol) u dimetilformamidu (10 ml) ukapava se 20 minuta u miješanu suspenziju natrijevog hidrida (60 %-tna suspenzija u mineralnom ulju; 1,78 g, 44,4 mmol) u dimetilformamidu (10 ml), na 0 "C, u atmosferi dušika.
The solid dispersion according to any of claims 1 to 12, wherein the solid dispersion is obtained by spray drying. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1, 2, 3, 5 ili 7, što dalje sadrži polimer.
Next, the sidechain is cleaved to form the compound of Formula 24 (where R7=CH3; R8=H; R9=PhOMe in generalized formula R of Scheme 7), as exemplified in Figure 29. 
Nakon toga se bočni lanac odcijepi od spoja formule 24 (R;=CH; i Rz =H; Re=PhOMe u općoj formuli R iz sheme 7), kao stoje prikazano kao primjer na slici 29.
The term COMPOUND EFFICACY shall mean a measurement of the ability of a compound to inhibit or stimulate receptor functionality, as opposed to receptor binding affinity. 
UČINKOVITOST SPOJA će značiti mjeru sposobnosti spoja da inhibira ili stimulira funkcionalnost receptora, što je suprotno afinitetu receptora prema vezivanju.
A method for manufacturing a print medium comprising the following steps: 
Postupak proizvodnje tiskovne podloge koji obuhvaća sljedeće korake:
The preparation according to claim 7, characterised by that said other polysaccharide is alginic acid having the molecular weight within the range from 1 000 to 1 000 000 g/mol and the ratio of the total number of D-mannuronic units to the total number of L-guluronic units within the range from 0.1 to 5, and being in its free form or in the form of a pharmacologically suitable salt which is a sodium, potassium, lithium, calcium, magnesium, zinc, cobalt, manganese or another salt or a mixture thereof. 
Pripravak prema zahtjevu 7, naznačen time da je navedeni drugi polisaharid alginska kiselina koja ima molekularnu težinu u rasponu od 1 000 do 1000000 g/mol i omjer ukupnog broja D-manuronskih jedinica prema ukupnom broju L-guluronskih jedinica u rasponu od 0.1 do 5, te je u slobodnom obliku ili u obliku farmakološki pogodne soli koja je natrijeva, kalijeva, litijeva, kalcijeva, magnezijeva, cinkova, kobaltova, sol mangana ili druga sol ili njihova smjesa.
The method of claim 9, wherein said sample is a tissue biopsy or a tumor biopsy. 
Spoj za uporabu u skladu s patentnim zahtjevom 3, pri čemu je navedeni uzorak uzorak biopsije tkiva ili uzorak biopsije tumora.
The peptide-derived molecule according to claims 1 to 3 having the amino acid sequence selected from the group consisting of: Ac-Pro-Pro-Pro-His-Pro-His-Ala-Arg-Ile-Lys-NH2; Ac-Pro-Pro-Pro-Pro-Pro-His-Pro-His-Ala-Arg-Ile-Lys-NH2; 
Molekula izvedena iz peptida prema zahtjevima 1 do 3, naznačena time da ima sekvencu aminokiselina koja se bira iz skupine koja se sastoji od: